SPHK1 and cancer: Upregulated expression of SPHK, particularly SPHK1, and increased levels of S1P have been linked with poor cancer prognosis and resistance to cytotoxic therapy agents in malignant cells from solid tumors, lymphomas, and leukemias (1, 6–8).